Chongqing Taiji Industry's subsidiary DSC158A has been approved to conduct clinical trials.

Chongqing Taiji Industry (600129.SH) announced that its wholly-owned subsidiary, Chongqing Taiji Industry Chongqing Fuling Pharmaceuticals Factory Co., Ltd., recently received a "Notice of Approval for Drug Clinical Trial" for the DSC158A tablet issued by the National Medical Products Administration. It is reported that DSC158A tablet is a new generation of RNA polymerase inhibitor independently developed by the company, intended for the treatment of adult influenza A and B. Preclinical studies have shown that DSC158A tablet can effectively improve symptoms in model mice at lower doses, while also demonstrating good tolerance and a large safety window. DSC158A tablet is classified as an "innovative drug not yet marketed domestically or internationally," with a registration category of Class 1 chemical drugs. As of now, the company has invested approximately RMB 25.41 million (unaudited) in this project.